Fosun Pharma's subsidiary, FamoTidine injection, received registration approval.

Recently, the application for registration of the famotidine injection by Jinzhou Aohong Pharmaceuticals, a subsidiary of Shanghai Fosun Pharmaceutical Holdings, was approved by the National Medical Products Administration. This chemical drug, independently developed by the group, is approved for the treatment of upper gastrointestinal bleeding caused by peptic ulcers. By 2025, the group has invested several million yuan in research and development of this drug. IQVIA CHPA data shows that the sales of famotidine injections in the domestic market in 2024 are approximately 1.377 billion yuan. This approval will enrich the group's product line, but the sales of the drug are affected by various factors, and there is uncertainty. Investors are reminded to pay attention to the risks.